Aurobindo Pharma Outlines Long-Term Growth Strategy Driven by Pen-G Expansion and Lannett Integration

Market snapshot: Aurobindo Pharma is positioning its manufacturing capabilities for long-term growth by ramping up domestic Penicillin-G production and expanding international sales. The company aims for 12,000 tons of Penicillin-G production by FY28, up from approximately 10,000 tons currently (as stated in the source alert; not independently verified). Additionally, management expects financial performance in FY28 to surpass FY27, backed by full revenue contributions from Lannett Company LLC, expanding China operations, and biosimilar portfolio growth.

Data Snapshot

• Aurobindo Pharma USA Inc. completed the 100% acquisition of Lannett Company LLC on June 29, 2026, for an aggregate purchase consideration of approximately ₹23,218.3 million ($250 million).
• Subsidiary Lyfius Pharma Private Limited operates a Penicillin-G manufacturing facility in Kakinada, Andhra Pradesh, with an annual capacity of 15,000 metric tonnes established under a ₹2,500 crore PLI scheme investment.
• The Government of India notified a Minimum Import Price policy on Penicillin-G, 6-APA, and Amoxicillin Trihydrate imports to safeguard domestic key starting material production.

Key Takeaways

• Aurobindo is working to scale Penicillin-G production toward 12,000 tons by FY28 from current levels of around 10,000 tons (as stated in the source alert; not independently verified).
• The company has submitted an anti-dumping application under regulatory guidelines (as stated in the source alert; not independently verified) to ensure fair market competition against foreign key starting material imports.
• FY28 performance is projected by management to surpass FY27, backed by full annual contributions from Lannett Company LLC, increased commercial volume in China, and biosimilars expansion.
• Vertical integration via Lyfius Pharma's 15,000 MT capacity Pen-G plant enhances domestic supply security for core active pharmaceutical ingredients.

SAHI Perspective

Aurobindo's strategic roadmap demonstrates a shift toward vertical manufacturing independence and high-barrier complex products. By scaling domestic production of Penicillin-G—supported by government policy initiatives like Minimum Import Prices—Aurobindo mitigates key starting material price volatility. Concurrently, the consolidation of Lannett Company LLC provides immediate access to US-based controlled substance manufacturing and inhalation products, offering revenue diversification beyond traditional generic formulations.

Market Implications

Increased domestic output of Penicillin-G strengthens local pharmaceutical supply chains and decreases reliance on bulk drug imports. Regulatory measures such as anti-dumping filings (as stated in the source alert; not independently verified) and Minimum Import Prices protect capital expenditure investments made under the PLI scheme, enhancing long-term EBITDA margin visibility for domestic producers.

Trading Signals

Market Bias: Bullish

Positive outlook is underpinned by the operational integration of the $250 million Lannett acquisition and commercial volume scaling at Lyfius Pharma's 15,000 MT annual capacity Penicillin-G facility.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients

Trigger Factors:

• Commercial volume growth and capacity utilization metrics for Penicillin-G at Lyfius Pharma
• Quarterly revenue integration and EBITDA margin contributions from Lannett Company LLC
• Regulatory decisions regarding trade protection and anti-dumping duties on key starting materials

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian active pharmaceutical ingredient sector continues to benefit from central government policy support under the Production Linked Incentive scheme, aimed at building domestic self-reliance for critical starting materials like Penicillin-G. Import regulations and price support mechanisms are designed to shield domestic manufacturers from predatory pricing, ensuring economic viability as commercial capacities scale up.

Key Risks to Watch

• Regulatory delay or non-imposition of requested anti-dumping protection measures on bulk drug imports
• Execution risks associated with scaling complex biosimilar production and expanding sales operations in China
• Potential compliance or integration overhead following US FDA inspections at newly acquired manufacturing sites

Recent Developments

In recent months, Aurobindo Pharma USA Inc. finalized its 100% acquisition of US-based Lannett Company LLC following regulatory FTC clearance. Subsequently, Lannett initiated commercial distribution of its generic equivalent of Advair Diskus in the US market. Operational monitoring continues following a routine US FDA inspection at Lannett's Seymour facility, which closed with four procedural observations.

Closing Insight

Aurobindo's execution across domestic PLI-backed key starting material plants and US-focused complex generic acquisitions establishes a strong operational foundation for multi-year revenue growth.

High Performance Trading with SAHI.